BR9913722A - Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo - Google Patents

Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo

Info

Publication number
BR9913722A
BR9913722A BR9913722-4A BR9913722A BR9913722A BR 9913722 A BR9913722 A BR 9913722A BR 9913722 A BR9913722 A BR 9913722A BR 9913722 A BR9913722 A BR 9913722A
Authority
BR
Brazil
Prior art keywords
active agent
human patient
delivering
lung
lungs
Prior art date
Application number
BR9913722-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Clarke
Mei-Chang Kuo
Cecily Lavor
Barry John Aldous
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of BR9913722A publication Critical patent/BR9913722A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
BR9913722-4A 1998-09-14 1999-09-13 Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo BR9913722A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14
PCT/US1999/021109 WO2000015262A1 (fr) 1998-09-14 1999-09-13 Administration par voie pulmonaire d'un agent actif sous forme de poudre seche

Publications (1)

Publication Number Publication Date
BR9913722A true BR9913722A (pt) 2001-05-29

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913722-4A BR9913722A (pt) 1998-09-14 1999-09-13 Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo

Country Status (44)

Country Link
EP (1) EP1117442A1 (fr)
JP (1) JP2002524535A (fr)
KR (1) KR20010075063A (fr)
CN (1) CN1317977A (fr)
AP (1) AP1374A (fr)
AR (1) AR022090A1 (fr)
AU (1) AU753014B2 (fr)
BG (1) BG105430A (fr)
BR (1) BR9913722A (fr)
CA (1) CA2343920A1 (fr)
CO (1) CO5130023A1 (fr)
CZ (1) CZ2001829A3 (fr)
DZ (1) DZ2892A1 (fr)
EA (1) EA003476B1 (fr)
EE (1) EE200100151A (fr)
GE (1) GEP20043257B (fr)
GT (1) GT199900156A (fr)
HK (1) HK1042231A1 (fr)
HN (1) HN1999000159A (fr)
HR (1) HRP20010189A2 (fr)
HU (1) HUP0103837A3 (fr)
ID (1) ID28845A (fr)
IL (2) IL141562A0 (fr)
IS (1) IS5878A (fr)
LT (1) LT4897B (fr)
LV (1) LV12658B (fr)
MA (1) MA25590A1 (fr)
MY (1) MY129282A (fr)
NO (1) NO20011251L (fr)
NZ (1) NZ510168A (fr)
OA (1) OA11781A (fr)
PA (1) PA8481901A1 (fr)
PE (1) PE20001061A1 (fr)
PL (1) PL195574B1 (fr)
SA (1) SA99200718B1 (fr)
SK (1) SK3442001A3 (fr)
TN (1) TNSN99173A1 (fr)
TR (1) TR200101182T2 (fr)
TW (1) TWI226248B (fr)
UA (1) UA76085C2 (fr)
UY (1) UY25711A1 (fr)
WO (1) WO2000015262A1 (fr)
YU (1) YU24201A (fr)
ZA (1) ZA200101995B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1392262A1 (fr) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PL373780A1 (en) 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2006513139A (ja) * 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
WO2004060352A1 (fr) * 2002-12-19 2004-07-22 Pharmacia Corporation Intermediaire pour formulation a caractere non-hygroscopique acceptable comprenant un bouchon hydroscopique
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
LT2708225T (lt) 2004-04-23 2019-04-10 Cydex Pharmaceuticals, Inc. Dpi kompozicija, turinti sulfoalkilo eterio ciklodekstrino
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
KR20070110418A (ko) * 2005-03-09 2007-11-16 오노 야꾸힝 고교 가부시키가이샤 입자 및 그 입자를 함유하는 제제
ES2526903T3 (es) 2005-10-26 2015-01-16 Cydex Pharmaceuticals, Inc. Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20100269819A1 (en) * 2006-08-14 2010-10-28 Sievers Robert E Human Powered Dry Powder Inhaler and Dry Powder Inhaler Compositions
CN101541311B (zh) * 2006-10-25 2013-01-23 大日本住友制药株式会社 不易结块的颗粒制剂
EP1925295A1 (fr) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Formule de poudre stable contenant un nouveau anticholinergique
JP2010524855A (ja) 2007-04-13 2010-07-22 ディフュージョン・ファーマシューティカルズ・エルエルシー 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用
BRPI0818119A2 (pt) 2007-10-31 2015-08-04 Diffusion Pharmaceuticals Llc Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena
ES2661215T3 (es) * 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
EP2445339B1 (fr) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Composé améliorant la diffusion et son utilisation avec un thrombolytique
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
US9682096B2 (en) 2012-05-02 2017-06-20 Janssen R & D Ireland Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
WO1993025198A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Poudre ultra-fine pour inhalation et production de cette poudre
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0954282B1 (fr) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
MY129282A (en) 2007-03-30
PA8481901A1 (es) 2002-04-25
AP1374A (en) 2005-02-28
OA11781A (en) 2005-07-26
IS5878A (is) 2001-03-05
BG105430A (en) 2001-12-29
CA2343920A1 (fr) 2000-03-23
NZ510168A (en) 2003-09-26
PE20001061A1 (es) 2000-10-08
HUP0103837A2 (hu) 2002-05-29
EP1117442A1 (fr) 2001-07-25
JP2002524535A (ja) 2002-08-06
GT199900156A (es) 2001-03-07
TWI226248B (en) 2005-01-11
PL195574B1 (pl) 2007-10-31
CO5130023A1 (es) 2002-02-27
LV12658B (lv) 2001-09-20
IL141562A0 (en) 2002-03-10
AU6039799A (en) 2000-04-03
ZA200101995B (en) 2002-03-11
ID28845A (id) 2001-07-05
TR200101182T2 (tr) 2001-09-21
GEP20043257B (en) 2004-06-25
TNSN99173A1 (fr) 2005-11-10
AU753014B2 (en) 2002-10-03
SK3442001A3 (en) 2001-11-06
CZ2001829A3 (cs) 2001-09-12
IL141562A (en) 2007-07-24
EA200100300A1 (ru) 2001-10-22
KR20010075063A (ko) 2001-08-09
EA003476B1 (ru) 2003-06-26
LT2001021A (en) 2001-11-26
LV12658A (lv) 2001-05-20
HRP20010189A2 (en) 2005-04-30
DZ2892A1 (fr) 2003-12-15
EE200100151A (et) 2002-06-17
MA25590A1 (fr) 2002-12-31
UY25711A1 (es) 1999-11-17
NO20011251D0 (no) 2001-03-13
NO20011251L (no) 2001-04-17
HK1042231A1 (zh) 2002-08-09
AR022090A1 (es) 2002-09-04
SA99200718B1 (ar) 2006-11-04
YU24201A (sh) 2003-08-29
HUP0103837A3 (en) 2002-11-28
UA76085C2 (en) 2006-07-17
AP2001002093A0 (en) 2001-03-31
HN1999000159A (es) 1999-11-11
LT4897B (lt) 2002-02-25
WO2000015262A1 (fr) 2000-03-23
PL346768A1 (en) 2002-02-25
CN1317977A (zh) 2001-10-17

Similar Documents

Publication Publication Date Title
BR9913722A (pt) Partìculas para fornecimento de um agente ativo aos alvéolos de um paciente humano, e método para a preparação das mesmas, método para fornecimento de um agente ativo aos pulmões de um paciente humano, e método para aumentar a quantidade de um agente ativo inalado depositado no pulmão profundo
Hickey et al. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives
NO20025873D0 (no) Meget effektiv levering av en stor terapeutisk mengde aerosol
DE69936268D1 (de) Verbesserte pulverformulierungen zur inhalation
PT1061901E (pt) Inalador de nicotina
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
DE59914603D1 (de) Multidosis-Trockenpulverinhalator mit Pulverreservoir
TR200101033T2 (tr) Akış direnci hafifletilmiş, aerosol halindeki aktif maddenin verilmesi
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
Ruijgrok et al. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats
ATE219942T1 (de) Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
Ferron Aerosol properties and lung deposition
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
EE04038B1 (et) Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
BR0013250A (pt) Formulações de suspensão aquosa ectoparasiticida de espinosinas
JPS60215092A (ja) 人体塗布用粉末エアゾ−ル組成物
Miller et al. Inhibition of hamster buccal pouch carcinogenesis by green coffee beans
TH59260B (th) การให้สารออกฤทธิ์ที่ได้รับการทำเป็นแอโรซอล
WO2003009873A3 (fr) Utilisations non therapeutiques de tensioactif pulmonaire
JP2000086480A (ja) 荒れ肌改善化粧料
JP2004002244A (ja) イヌまたはネコ体表の発毛・育毛方法
TH59260A3 (th) การให้สารออกฤทธิ์ที่ได้รับการทำเป็นแอโรซอล

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.